An update on clinical trials for cutaneous lupus erythematosus

The Journal of Dermatology, Journal Year: 2024, Volume and Issue: 51(7), P. 885 - 894

Published: March 15, 2024

Cutaneous lupus erythematosus (CLE) comprises dermatologic manifestations that may occur independently or with systemic (SLE). Despite advancements in refining CLE classification, establishing precise subtype criteria remains challenging due to overlapping presentations and difficulty distinguishing morphology. Current treatments encompass preventive measures, topical therapies, approaches. Hydroxychloroquine glucocorticoids are the sole US Food Drug Administration (FDA)-approved medications for CLE, numerous off-label available. However, these often not covered by insurance, imposing a significant financial burden on patients. The exclusion of most patients, particularly those without concurrent SLE, from trials designed SLE has resulted lack targeted CLE. To develop effective treatments, validated outcome measures tracking patient responsiveness essential. Lupus Erythematosus Disease Area Severity Index is widely utilized its reliability, validity, ability differentiate between skin activity damage. In contrast, FDA mandates use Investigator's Global Assessment, five-point Likert scale related lesion characteristics, skin-related therapeutic trials. It requires disease resolve almost completely demonstrate improvement, which can be difficult when there residual erythema incomplete clearance meaningfully improved perspective. Various classes target diverse pathways, allowing tailored treatment based patient's inflammatory profile, resulting outcomes. Promising drugs include anifrolumab (anti-type 1 interferon), deucravacitinib (allosteric tyrosine kinase 2 inhibitor), litifilimab (plasmacytoid dendritic cell-directed therapy), iberdomide (cereblon-targeting ligand), belimumab (B-cell directed therapy). impact quality life, options remain inadequate. While promising cutaneous emerging, it crucial underscore urgency skin-focused outcomes implementation assess effectiveness clinical

Language: Английский

---

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 16, 2024

Type I interferons (IFN-Is) are important players in the immunopathogenesis of systemic lupus erythematosus (SLE). Pathogenic events patients with SLE potent triggers IFN-I induction, yet may induce or initiate leading to these events. Because blocking is effective some clinical manifestations patients, concerns about efficacy anti-IFN-I therapy nephritis remain. Tissues from kidney biopsies revealed infiltration various immune cells and activation inflammatory signals; however, their correlation renal damage not clear, which raises serious how critical role among potential contributors pathogenesis nephritis. This review addresses several issues related roles SLE, especially nephritis, including (1) contribution development SLE; (2) evidence supporting association nephritis; (3) therapies targeting downstream signaling molecules (4) findings challenging therapeutic benefits (5) a perspective associated biologics for treatment. In addition providing clear pictures this lately published observations trials on topic.

Language: Английский

---

Novedades en la inmunoterapia de las enfermedades autoinmunes del tejido conectivo. Parte I: lupus eritematoso cutáneo

Piel, Journal Year: 2024, Volume and Issue: 39(10), P. 644 - 650

Published: July 26, 2024

---

Innovations in Cutaneous Lupus

Dermatologic Clinics, Journal Year: 2024, Volume and Issue: 43(1), P. 123 - 136

Published: Sept. 14, 2024

Language: Английский

---

Cutaneous Lupus Erythematosus

Published: Jan. 1, 2024

Language: Английский

---